Disc Medicine Inc Quick Ratio (IRON) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
IRON's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Disc Medicine Inc 's Cash & cash equivalent grew by 83.08 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Disc Medicine Inc 's Quick Ratio to 44.03, above Disc Medicine Inc average Quick Ratio.
Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Quick Ratio than Disc Medicine Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 55 to 90.
Disc Medicine Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for serious hematologic diseases, has recently announced a significant financial milestone that positions the company for sustained growth and innovation in the field. The company secured a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), which will support various upcoming clinical studies and enhance its balance sheet as the company prepares to present at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024.Key Financial Developments:1. Non-Dilutive Financing: The $200 million loan from Hercules Capital is a crucial financial arrangement for Disc Medicine, allowing it to fund critical studies without diluting the current shareholdersn equity. 2. Strategic Use of Funds: The financing will facilitate the initiation of key clinical studies: - A confirmatory study of bitopertin for erythropoietic protoporphyria (EPP). - A Phase 2 study of DISC-0974 for anemia of myelofibrosis (MF). - A multiple-dose study for anemia in non-dialysis dependent chronic kidney disease (NDD-CKD). - A Phase 2 study of DISC-3405 in polycythemia vera (PV).
In a significant move towards advancing its mission of revolutionizing the treatment landscape for serious hematologic diseases, Disc Medicine, Inc., a prominent clinical-stage biopharmaceutical company, has announced the pricing of an underwritten offering of its common stock. This offering paves the way for the company to generate approximately $178.0 million in aggregate gross proceeds, representing a significant milestone in its growth strategy. The news has garnered substantial attention within the biopharmaceutical industry and underscores Disc Medicine s commitment to developing innovative therapies for patients in need. Underwritten Offering Details: Disc Medicine, Inc. has successfully priced the underwritten offering of 4,944,000 shares of its common stock at $36.00 per share. All of the securities being sold in the offering are offered exclusively by Disc Medicine. It is worth noting that the offering price reflects both the company s strong market positioning and investors confidence in its potential. The anticipated proceeds, which do not include underwriting discounts, commissions, and other offering expenses, are expected to significantly bolster Disc Medicine s financial strength and support the advancement of its clinical programs.
On the trailing twelve months basis IRON Cash & cash equivalent more than doubled by 105.67 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Disc Medicine Inc 's Quick Ratio to 37.8, above IRON average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 416 other companies have achieved higher Quick Ratio than Disc Medicine Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2122 to 3363.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
